• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4598788)   Today's Articles (8963)   Subscriber (49356)
Number Citation Analysis
101
Garcia GCTE, Gorphe P, Hartl D, Ammari S, Even C, Tao Y, Balleyguier C, Varoquaux A, Bidault F. Computed tomography evaluation after induction chemotherapy for T3 laryngeal cancer: Does response correlate with vocal cord mobility? Oral Oncol 2019;90:13-16. [PMID: 30846170 DOI: 10.1016/j.oraloncology.2019.01.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Revised: 01/17/2019] [Accepted: 01/19/2019] [Indexed: 10/27/2022]
102
Schernberg A, Canova C, Blanchard P, Gorphe P, Breuskin I, Mirghani H, Moya-Plana A, Janot F, Bidault F, Chargari C, Bellefqih S, Ruffier A, Even C, Nguyen F, Temam S, Tao Y. Prognostic factors in patients with soft palate squamous cell carcinoma. Head Neck 2019;41:1441-1449. [PMID: 30636178 DOI: 10.1002/hed.25598] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2017] [Revised: 10/02/2018] [Accepted: 12/05/2018] [Indexed: 01/04/2023]  Open
103
Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer 2018;107:142-152. [PMID: 30576970 DOI: 10.1016/j.ejca.2018.11.015] [Citation(s) in RCA: 163] [Impact Index Per Article: 27.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2018] [Revised: 11/09/2018] [Accepted: 11/10/2018] [Indexed: 01/12/2023]
104
Hilberer A, Laurent G, Lorin A, Partier A, Bobroff J, Bouquet F, Even C, Fischbach JM, Marrache-Kikuchi CA, Monteverde M, Pilett B, Quay Q. Temperature-dependent transport measurements with Arduino. PAPERS IN PHYSICS 2018. [DOI: 10.4279/pip.100007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]  Open
105
Ruffier-Loubière A, Tao Y, Nguyen F, Moya-Plana A, Even C, Berthold C, Casiraghi O, Temam S, Blanchard P. Réirradiations des carcinomes nasopharyngés en récidive locale : analyse de l’efficacité et de la toxicité sur une série de 2005 et 2018. Cancer Radiother 2018. [DOI: 10.1016/j.canrad.2018.07.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
106
Even C, Daste A, Saada-Bouzid E, Fayette J, Kaminsky-Forrett MC, Zanetta S, Prevost A, Lefebvre G, Borel C, Cupissol D, Huguet F, Delord JP, Baste Rotllan N, Delaye J, Jallut I, Vintonenko N, Bourhis J, Guigay J, Texier M, Auperin A. TOPNIVO: A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of the head and neck (R/M SCCHN): First results on behalf of the UNICANCER Head&Neck Group and the GORTEC. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
107
Fayette J, Lefebvre G, Posner M, Bauman J, Salas S, Even C, Saada-Bouzid E, Seiwert T, Colevas D, Calmels F, Zerbib R, Boyer Chammard A, Cohen R. Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
108
Houessinon A, Verlingue L, Hollebecque A, Even C, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Balheda R, Michot JM, Gazzah A, Marabelle A, Michiels S, Rouleau E, Breuskin I, de Baere T, Angevin E, Scoazec JY, Soria JC, Massard C. Molecular screening in advanced cancer patients with head and neck cancers: A retrospective analysis of the MOSCATO-01 trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
109
Ho A, Chau N, Bauman J, Bible K, Chintakuntlawar A, Cabanillas M, Wong D, Braña Garcia I, Brose M, Boni V, Even C, Razaq M, Mishra V, Bracken K, Wages D, Scholz C, Gualberto A. Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.002] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
110
Gazzah A, Boni V, Soria JC, Calles A, Even C, Doger B, Mahjoubi L, Bahleda R, Ould-Kaci M, Esler A, Nazabadioko S, Calvo E. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. Eur J Cancer 2018;104:1-8. [PMID: 30278378 DOI: 10.1016/j.ejca.2018.07.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Accepted: 07/12/2018] [Indexed: 12/29/2022]
111
Herrera Gomez R, Mezquita L, Auclin E, Saleh K, Baste Rotllan N, Iacobs M, Bursuc S, Mayache Badis L, Ferrand F, Casiraghi O, Temam S, Breuskin I, Tao Y, Besse B, Even C. Association of LIPI score with immune checkpoint inhibitors (ICI) outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients (pts). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy287.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
112
Palomar Coloma V, Bravo P, Lezghed N, Mayache-Badis L, Herrera Gómez RG, Iacob M, Nicouleau L, Desmaris R, Tao Y, Leibu C, Matias M, Lemare F, Even C, Annereau M, Ferté C. High incidence of cetuximab-related infusion reactions in head and neck patients. ESMO Open 2018;3:e000346. [PMID: 30094066 PMCID: PMC6069910 DOI: 10.1136/esmoopen-2018-000346] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Revised: 05/05/2018] [Accepted: 05/07/2018] [Indexed: 11/04/2022]  Open
113
Ferris RL, Blumenschein GR, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-ct116] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
114
Cohen R, Fayette J, Posner M, Lefebvre G, Bauman J, Salas S, Even C, Seiwert T, Colevas D, Jimeno A, Saada E, Burtness B, André P, Paturel C, Bonnafous C, Soulié AM, Tirouvanziam-Martin A, Zerbib R, Boyer-Chammard A. Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-ct158] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
115
Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist 2018;23:1079-1082. [PMID: 29866947 DOI: 10.1634/theoncologist.2017-0674] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2017] [Accepted: 03/06/2018] [Indexed: 12/12/2022]  Open
116
Saleh K, Daste A, Martin N, Pons-Tostivint E, Auperin A, Herrera-Gómez RG, Baste N, Bidault F, Guigay J, Le Tourneau C, Saada E, Even C. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.6015] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
117
Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 2018;81:45-51. [PMID: 29884413 DOI: 10.1016/j.oraloncology.2018.04.008] [Citation(s) in RCA: 517] [Impact Index Per Article: 86.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2018] [Accepted: 04/10/2018] [Indexed: 02/07/2023]
118
Siu L, Even C, Mesía R, Daste A, Krauss J, Saba N, Nabell L, Ready N, Garcia I, Kotecki N, Zandberg D, Gilbert J, Mehanna H, Jarkowski A, Melillo G, Armstrong J, Fayette J. A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2017.12.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
119
Ho A, Chau N, Garcia IB, Ferte C, Even C, Burrows F, Kessler L, Mishra V, Magnuson K, Scholz C, Gualberto A. Preliminary Results From a Phase 2 Trial of Tipifarnib in HRAS-Mutant Head and Neck Squamous Cell Carcinomas. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2017.12.156] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
120
Tao Y, Faivre L, Laprie A, Boisselier P, Ferron C, Jung G, Racadot S, Gery B, Even C, Breuskin I, Bourhis J, Janot F. OC-0272: Twice daily reirradiation with cetuximab vs once daily chemoRT after surgery in head and neck cancer. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)30582-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
121
Boros A, Blanchard P, Gorphe P, Breuskin I, Even C, Nguyen F, Deutsch E, Bidault F, Janot F, Temam S, Mirghani H, Tao Y. EP-1158: Prognostic factors and role of neck dissection in N3 head and neck cancers treated with radiotherapy. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31468-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
122
Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, Even C, Fayette J, Guigay J, Loirat D, Peyrade F, Alt M, Gal J, Le Tourneau C. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2018;28:1605-1611. [PMID: 28419181 DOI: 10.1093/annonc/mdx178] [Citation(s) in RCA: 423] [Impact Index Per Article: 70.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Indexed: 12/20/2022]  Open
123
Leduc C, Adam J, Louvet E, Sourisseau T, Dorvault N, Bernard M, Maingot E, Faivre L, Cassin-Kuo MS, Boissier E, Dessoliers MC, Robin A, Casiraghi O, Even C, Temam S, Olaussen KA, Soria JC, Postel-Vinay S. TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open 2018;3:e000257. [PMID: 29344407 PMCID: PMC5761289 DOI: 10.1136/esmoopen-2017-000257] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2017] [Revised: 08/22/2017] [Accepted: 08/23/2017] [Indexed: 01/05/2023]  Open
124
Ho A, Chau N, Wong DJ, Cabanillas ME, Bauman J, Brose MS, Bible K, Boni V, Brana I, Ferte C, Even C, Burrows F, Kessler L, Mishra V, Magnuson K, Scholz C, Gualberto A. Abstract LB-A10: Preliminary results from a phase 2 proof of concept trial of tipifarnib in tumors with HRAS mutations. Clin Trials 2018. [DOI: 10.1158/1535-7163.targ-17-lb-a10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
125
Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EM, Saraf S, Thanigaimani P, Cheng JD, Hansen AR. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J Clin Oncol 2017;35:4050-4056. [DOI: 10.1200/jco.2017.73.3675] [Citation(s) in RCA: 252] [Impact Index Per Article: 36.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
PrevPage 5 of 10 12456910Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA